VivekNaranbhaiMDPhD, DPhil

Intern

Dr. Naranbhai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency.
Anna M Zhang, Ahmed Elmoursi, Daniel V DiGiacomo, Baijun Zhou, Megha Tandon
The Journal of Allergy and Clinical Immunology. Global. 2024-05-01
1 citations
In silico clinical studies for optimal COVID-19 vaccination schedules in patients with cancer.
Chrysovalantis Voutouri, C Corey Hardin, Vivek Naranbhai, Mohammad R Nikmaneshi, Melin J Khandekar
Cell Reports. Medicine. 2024-03-19
Dynamic heterogeneity in COVID-19: Insights from a mathematical model.
Chrysovalantis Voutouri, C Corey Hardin, Vivek Naranbhai, Mohammad R Nikmaneshi, Melin J Khandekar
Plos One. 2024-01-01

Killer Cell Immunoglobulin–like Receptor 3DL1 Variation Modifies HLA-B*57 Protection Against HIV-1February 2018
Killer Cell Immunoglobulin–like Receptor 3DL1 Variation Modifies HLA-B*57 Protection Against HIV-1February 2018

Texas Schools Can Issue Mask Mandates, Federal Judge Rules; 900K Kids Ages 5-11 Jabbed in First Days of Rollout: COVID UpdatesNovember 11th, 2021
More Evidence That COVID Vaccines Are Safe for Cancer PatientsNovember 10th, 2021
Addressing Vaccine Hesitancy in Massachusetts’ Hardest-Hit CommunityJuly 15th, 2021
Join now to see all